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Abstract: Data now indicates that in addition to genetic alterations/mutations, human cancer
cells exhibit important changes in their epigenome. In the context of this review, we define the
epigenome as the chemical compounds and/or proteins that can interact with nuclear DNA to direct
the specific and localized activation or silencing of genes to control the production of cellular proteins
(directly or indirectly) in a given cell. Our ever-growing knowledge of how the epigenome can affect
cellular processes has largely changed our view of cancer being a solely genetic disease. Nowadays,
cancer is largely defined and characterized by the dynamic changes in both the genome and
epigenome, which function together and contribute concomitantly to cancer initiation and progression.
Since epigenetic modifications are crucial processes involved in controlling cellular identity and
lineage fate, perturbations in this layer of gene regulation can contribute to the acquisition of new
cellular characteristics different than those that were “initially” intended. For example, aberrant
epigenetic alterations may transform normal non-cancer cells into cancer stem cells (CSCs), endowing
them with the loss of differentiation and the acquisition of stem-like characteristics. In this review,
we will focus our discussion on CSCs in the context of pancreatic ductal adenocarcinoma (PDAC).
We will discuss how different epigenetic modifications create a landscape that can impact CSC
identity and the way this small sub-population of cells contributes to tumor initiation, progression,
and resistance to therapy. Moreover, we will highlight the latest discoveries in epigenetic-based
therapies as a means of targeting CSCs.
Keywords: pancreatic cancer; cancer stem cells; plasticity; epigenetics; methylation; acetylation;
non-coding RNA
1. Introduction
The general model of cancer progression has been viewed as a multistep process of transformation
of normal cells into malignant cells driven by genetic alterations [1]. Nowadays, however, we know
that cancer is not solely a genetic disease [2,3], and over the past decade, a vast amount of research data
has unequivocally shown that solid tumors are also not simply a ‘mass’ of homogeneous tumor cells,
but rather a very complex ecosystem consisting of tumor cells and other cell types, such as endothelial,
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hematopoietic, stromal and immune cells, all of which can influence the biology and overall status of
the tumor as a whole. Importantly, there exists both heterogeneity across tumor cells and a defined
hierarchical structure within the tumor, with a small sub-population of cells with stem-like properties,
known as cancer stem cells (CSCs), residing at the apex of this hierarchy. Just as with normal stem cells,
CSCs possess the ability to self-renew and divide both symmetrically and asymmetrically. Moreover,
CSCs can differentiate giving rise to more differentiated progenies, including progenitor cells, transient
amplifying cells and more differentiated cells, all of which form part of the tumor bulk. Lastly, and more
importantly, these cells possess high tumor-initiating capacity and can form tumors that recapitulate
the heterogeneity of the original tumor from which they were derived when injected in vivo in mouse
models. Hence, by definition, self-renewal and differentiation of CSCs leads to the production of all
cell types present within the tumor bulk, thereby driving both tumor hierarchy and heterogeneity [4].
It is important to note that the idea that CSCs are the source of tumor heterogeneity represents the main
principle of the CSC model. This contrasts with the stochastic model (or clonal evolution model), which
argues against particular cell populations driving tumor heterogeneity and claims that all tumors are
biologically homogeneous. Thus, the stochastic model would argue that functional heterogeneity in
tumor cells would be due to random or stochastic influences that alter the behavior of individual cells
in the tumor [5]. Despite the underlying differences between both models, research over the past two
decades has shown that these two models are not mutually exclusive and can be used in combination
to explain tumor heterogeneity [6–8]. For example, Navin et al. provide an elegant explanation for
tumor heterogeneity by suggesting that the tumor mass is continuously evolving, with some CSC
clones becoming more dominant than others in terms of proliferation, adaptation, metastatic potential
or chemoresistance at given times during the evolution of the tumor [9]. Thus, the representation
of CSC clones at a particular time is just a snapshot of the state of tumor at a specific time during
its evolution.
Studies in hematopoietic malignancies have provided the foundation for our understanding
of CSCs. As early as 1935, Furth and Kahn [10] would be the first to suggest that CSC existed by
showing that single leukemic cells could confer systemic disease when transplanted into recipient mice.
This study, together with later ones, pointed towards the idea that functional heterogeneity exists
within tumors. That is, not every tumor cell is able to proliferate to form a colony in vitro or to give
rise to a tumor when transplanted in vivo. These concepts would inevitably lead to the birth of the
CSC concept. In the early 1990s, Dick and colleagues, using limiting dilution in vivo transplantation
assays together with fluorescence-associated cell sorting, showed that only a small fraction of tumor
cells isolated from acute myeloid leukemia (AML) patients, with a characteristic cell-surface marker
signature, were able to establish leukemia in recipient immunocompromised mice [11]. Following
their identification in hematopoietic cancers, CSCs would soon be discovered in solid tumors, the first
being breast cancer. In 2003, Al-Hajj et al., using the mammary stem cell markers CD44 and CD24,
would isolate for the first time breast CSCs [12]. Soon after, CSCs would be identified and isolated from
several solid tumors including brain, liver, ovary, prostate, lung, melanoma, colon and pancreatic ductal
adenocarcinoma (PDAC), by using different cell-surface markers or via side population (SP) functional
analysis [12–15]. For PDAC, Hermann et al., demonstrated that CD133-positive cells could form more
tumors than their CD133-negative counterparts [16]. While large numbers of CD133-negative cells
could not induce tumor formation, small numbers of CD133-positive cells were found to be very
tumorigenic. In liver cancer, such as hepatocellular carcinoma (HCC), several cell surface markers
such as EpCAM, CD133, cytokeratin 7 and 19 have been used as specific markers for liver CSCs.
Even though cell surface markers are widely used for CSC identification in different tumors, there
exist inherent limitations linked to the use of markers for the identification and isolation of CSCs.
For example, the expression of CSC-associated cell surface markers is not exclusive to CSCs, they
can change after chemotherapy or their levels can be modulated by the microenvironment. Thus,
additional experiments, such as assessing in vivo tumor-initiating capacity or in vitro self-renewal
ability, should always be conducted to support the stemness features of putative “CSC” populations.
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2. Epigenetic Landscape of CSCs
Several studies have attempted to decipher the genetic and epigenetic mechanisms behind the
establishment and maintenance of CSCs. Understanding that epigenetic mechanisms regulate key
transcriptional programs in adult stem cells, such as those involved in controlling self-renewal and
differentiation, several studies have suggested that similar mechanisms likely also govern CSC-genesis
and the maintenance of key CSC features [17–19]. The observation that the CSC population is rare
across many different cancers implies that epigenetic rather than genetic differences are the underlying
drivers for why CSCs are functionally different from their non-CSC counterparts. Moreover, while
it was generally believed that epigenetic differences would have to be largely irreversible to prevent
non-CSCs from efficiently reverting to a CSC state, this concept has been recently challenged. Using
mouse models of colorectal cancer (CRC), two groups recently showed that non-CSCs can convert
into CSCs when the CSC pool is eliminated [20,21]. Thus, the regulation of epigenetic marks and the
epigenome of CSCs and non-CSCs may be more complex and plastic than previously believed.
The epigenetic landscape of any cell represents the combination of 4 different mechanisms of
non-genetic gene regulation. These mechanisms include (1) DNA methylation and/or de-methylation,
which represent a covalent modification of DNA; (2) Histone modification, representing covalent
modification of histone tails; (3) non-coding RNA molecules and (4) Nucleosome remodeling. Below
and in Figure 1, we discuss how the first three processes participate in CSC biology, specifically in
pancreatic CSCs.
2.1. DNA Methylation and De-Methylation in CSCs
Of the epigenetic modifications known, DNA methylation is the most well-studied. In general,
DNA methylation, together with histone modifications and chromatin-associated proteins, mediates
stable gene silencing, regulates gene expression and functions in chromatin architecture [22]. While
non-CpG methylation has been observed in induced pluripotent stem cells (iPSCs) [23], DNA
methylation occurs predominantly at CpG dinucleotides in mammals [24]. CpG dinucleotides are
DNA regions where a cytosine is followed by a guanine. They are not evenly distributed across the
genome but rather are concentrated in CpG-rich stretches of DNA, known as CpG islands, typically
stretches of 500–1500 base pairs of DNA with CG:GC ratios of greater than 0.6 [25].
The class of enzymes known as DNA methyltransferases (DNMTs) mediate the methylation
reaction of cytosine by catalyzing the transfer of the methyl group from S-adenosyl-methionine
onto cytosine. This family of enzymes consists of 5 members: DNMT1, DNMT2, DNMT3A,
DNMT3B, and DNMT3L [26]. Of these 5 members, DNMT2 functions as an RNA methyltransferase
rather than a methyltransferase for DNA [27], and DNMT3L does not contain a methyltransferase
catalytic domain. Thus, only DNMT1, DNMT3A and DNMT3B are considered true functional DNA
methyltransferases [28]. After DNA replication, the maintenance of cytosine methylation at CpG
dinucleotides is carried our primarily by DNMT1 [29]. DNMT1 copies the methylation patterns from
the parental strand of DNA to the newly synthesized DNA strand [30]. While DNMT3A and DNMT3B
are also capable of methylating hemimethylated DNA, these two methyltransferases function more
during embryogenesis as de-novo methyltransferases [31].
DNA methylation can contribute to gene silencing in various ways, such as creating a “physical
barrier” whereby transcription factors cannot access their target-binding sites. Such “blocking” has
been observed for the genes MYC and MLTF. Alternatively, DNA methylation can facilitate the
binding of methyl-binding domain proteins to DNA, mediating gene repression via interactions with
histone deacetylases (HDACs) [32,33]. Thus, DNA methylation can silence genes and even non-coding
genomic regions via a variety of different mechanisms.
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Figure 1. Epigenetic regulation of Cancer Stem Cells. Graphical summary of the epigenetic mechanisms
regulating CSCs. DNA methylation, histone modifications and non-coding RNA molecules (lncRNAs
and miRNAs) work together to modify CSC biology and plasticity. (A) The DNMT1 methyltransferase
methylates CpG sites contributing to differential methylation of genes important for stemness and
differentiation (Diff.). It is likely that in parallel, TET proteins generate 5hmC conferring active or
passive demethylation. While several studies have shown that DNMT1 is over expressed in CSCs,
the level of TET proteins in CSCs is yet to be determined. Non-coding RNA molecules, specifically
iRNA and lncRNA molecules add an additional layer of complexity and regulation; (B) miRNAs
can target several mRNAs that play important roles as pro- or anti-CSC regulators. For example,
the miR17-92 cluster targets several genes important for pancreatic CSC-ness and chemoresistance,
and as such the expression of this cluster is downregulated in CSCs. On the other hand, miRNAs
that promote EMT features, such as the loss of cell adhesion, are upregulated in CSCs. Examples
include miR-9 (target: E-cadherin), miR-194 (target N-cadherin), miR-661 (target: Nestin and Star1).
(C) lncRNAs can represent a bridge between the many layers of epigenetic gene regulation, interacting
with, for example, histone modifiers or serving as ceRNAs for miRNAs; (D) Genes important for
stemness, differentiation (Diff.) and metabolic reprogramming are found with active and inhibiting
histone tags, and histone-modifying enzymes are expressed at different levels between CSCs and their
non-CSC counterparts, such as MLL1, EZH2 and KDM6A; (Center) The plasticity of differentiated
cancer cells and CSCs and their ability to quickly transdifferentiate could be a due to a balance between,
high and/or low levels of DNA methylation, hydroxymethylation, histone acetylation or methylation,
together with tumor-suppressive/oncogenic miRNAs and lncRNAs.
The literature has demonstrated that methylation changes follow cancer development and
progression [34]. Likewise, studies in embryonic stem cells (ESCs) show that during differentiation
and cell fate decision, a major switch in the methylation landscape occurs [35], reinforcing the idea
that methylation is an important epigenetic process linked to cellular differentiation. Adult stem
cells also exhibit similar methylation changes in specific tissues under both normal and pathological
conditions, including cancer [36]. Thus, methylation likely plays a very important role in cancer
development and/or progression. Indeed, many studies have already shown that in different tumor
cells populations, differential DNA methylation could account for the expression of key genes, such
as stem cell marker genes [37]. In breast cancer, for example, it was shown that the CSC genes CD44,
CD133 and Musashi-1 (MSI1) are regulated by the methylation of CpG regions in their promoters, and
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hypomethylation can activate these CSC genes in clinically more aggressive subtypes (triple- negative
breast cancer) [38–40]. Moreover, a study by Sun et al. comparing methylation profiles in invasive and
non-invasive pancreatic cancer cells revealed a significant correlation between the methylation profile
and the expression of key pathways, such as NF-κB signaling, in the two cell populations studied.
For example, genes such as BIMP, TNFR and CD49 were demethylated in the invasive population
but methylated in the non-invasive fraction [41]. In addition, the authors also found BMP4, GATA6
and SOX9 to be differentially methylated among invasive and non-invasive cells. This is of particular
interest as these genes have also been shown to play important roles in multiple cancer types.
Proteins involved in the establishment and maintenance of DNA methylation have also been
identified as drivers of CSC formation. Trowbridge et al. found that the development of leukemia
was blocked by abrogation of DNMT1; haploinsufficiency of DNMT1 induced re-expression of tumor
suppressor genes, impairing CSC self-renewal and attenuating leukemia progression [42]. In breast
cancer, mammary stem and progenitor cell populations were significantly reduced in Dnmt1-knockout
mice, suggesting a critical role for DNMT1 in the expansion and maintenance of mammary stem
cells [43]. Also, in lung cancer, up regulation of DNMT1 by Interleukin (IL)-6 has been shown to be
associated with an increase in the CSC population, which the authors show to be due to methylation of
TP53 and p21 (WAF1/CIP1) [44]. Similar to breast cancer and leukemia, lack of DNMT1 also impaired
the stemness of lung CSCs. In PDAC, our recent publication [45] indicates that pancreatic CSCs are
dependent on DNMT1 for their in vivo and in vitro stemness properties. Specifically, pancreatic CSCs
show high expression of DNMT1, and abrogation of DNMT1 impaired their self-renewal and promoted
their differentiation toward non-stem populations. Thus, our and other studies published to date
indicate that inhibition of DNMT1 may prove to be a therapeutic option to modulate and subsequently
eliminate CSCs in various tumor types.
In general DNA methylation was considered to be a very stable chromatin modification process;
however, studies examining global DNA methylation throughout embryonic development have shown,
in early zygotes, that global loss of DNA methylation occurs, especially in the male pronucleus [46].
High-resolution genome-wide mapping of methylation has also confirmed that DNA methylation is not
stable and can also be modified in iPSCs and differentiated cells [47]. Together, these studies, indicate
an active enzymatic process within cells that can erase or alter DNA methylation. The ten-eleven
translocation (TET) family proteins, which include TET1, TET2 and TET3, actively participate in
DNA demethylation, via iron and α-ketoglutarate dependent 5-methylcytosine dioxygenase activity,
converting 5-methylcytosine (5mC) bases to 5-hydroxymethylcytosine (5-hmC) bases [48,49]. Based
on their distinct expression patterns, it is believed that the three TET proteins have non-overlapping
functions. For example, TET1 and TET2 are highly expressed in ESCs, TET2 is also abundantly
expressed in hematopoietic cells, and TET3 expression has been detected in oocytes [50]. In addition,
emerging evidence suggests that apart from their well-studied DNA modification roles in ESC
and neuronal systems, TET-mediated DNA modifications may also be important mediators of
tumorigeneses, as detailed below.
Somatic mutations in TET proteins have been detected in CRC, and mutations and/or deletions
of TET2 have been described in clear-cell renal cell carcinoma [51] and metastatic castration-resistant
prostate cancer [52]. The observation that the decrease in 5-hmC levels and/or TET expression
correlates with aggressive tumor growth, shown in several studies, supports the idea that TET proteins
might play important tumor suppressor roles in certain types of solid tumors [53,54]. A 2013 study
using the HpaII tiny fragment Enrichment by Ligation-mediated PCR beta-glucosyl transferase (β-GT)
assay, known as HELP-GT, found redistribution of 5-hmC sites in PDAC cells [55]. Interestingly, the
authors observed that the enrichment was more variable in promoters, CpG islands and shores,
and redistribution of many 5-hmC sites occurred in promoters known to play a role in PDAC
tumorigenesis and metastasis, such as GATA6, whose expression has been directly linked to EMT [56],
a CSC-associated phenotype. These results suggest that redistribution of 5-hmC peaks in PDAC
correlates with sites of active transcription allowing activation of cancer-promoting oncogenes that
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are linked to these differently hemi-methylated sites. Interestingly, we showed that at the DNA level,
pancreatic CSCs display a hypermethylated phenotype, which is most probably due to the higher
expression levels of methyltransferase proteins such as DNMT1 [45]. These cells may very well display
lower levels of hydroxymethyl marks and/or their distribution could vary compared to their non-CSC
counterparts. Unfortunately, very few reports exist regarding 5-hmC and TET proteins in pancreatic
cancer and pancreatic CSCs, thus future studies are needed to shed more light on if and how these
processes are involved in pancreatic CSC biology.
2.2. Histone Modification in PDAC and CSCs
Post-translational modification of histone tails is an evolutionary conserved mechanism that plays
a critical role in regulating the chromatin state and gene activation [57,58]. These modifications can
structurally change the chromatin to facilitate or exclude protein complexes from interacting with
specific DNA regions. Thus, histone modifications can influence gene transcription, by altering their
activity, which could potentially contribute to oncogenic transformation and cancer progression.
Five types of histones are known and include histone 2A (H2A), H2B, H3, and H4, and one linker
histone, H1 (or H5), that is not present in the nucleosome bead, but helps to secure the DNA that is
wound around each histone octamer. Approximately 146 base pairs of DNA are wrapped, in 1.67
left-handed super helical turns, around each nucleosome bead, consisting of two copies of each of the
core histones H2A, H2B, H3 and H4 [57–59].
The amino acid residues located on the N- and C-terminal tails of histones can be post-translationally
modified via process such as methylation, acetylation, phosphorylation, ubiquitination and SUMOylation.
All these modifications are generally referred to as histone marks and they form a special kind of
language that nowadays we call “histone code”. Similar to genetic code, epigenetic “tagging” represents
a fundamental regulatory mechanism that has an impact on most, if not all, chromatin processes [22].
The dynamic addition or removal of post-translational modifications from histone tails is mediated by
several different histone-modifying enzymes. The “writers” and “erasers” of histone marks include many
enzymes, such as histone acetyltransferases, HDACs, histone methyltransferases, histone demethylases,
histone ubiquitinating enzymes, and histone deubiquitinating enzymes, all of which vary in their ability
to recognize and alter the amino acid residues of histone tails [60–62].
Of all modifications, one of the most widely studied are alterations of lysine modifications
on the histone H3 N-terminal tail, including lysine methylation, acetylation, and phosphorylation.
Lysine methylation marks on chromatin associated with promoter regions have been shown to
be correlated with transcriptional activation (e.g., histone 3, lysine 4 trimethylation) or silencing
(e.g., H3K9me3 or H3K27me3), usually through recruitment of co-effectors or polycomb group
proteins [63]. Furthermore, the histone code can be very complex as a specific regulatory region
may be associated with not only one type of mark but with multiple marks. For example, genes whose
promoters are marked with H3K4me3 and H3K27me3 are called bivalent genes. These genes are
expressed at low levels and are said to be “poised” to be activated upon a stimulating signal [64].
Bivalent genes are a frequent feature in stem cells and pluripotent cells, where these genes can be
activated by loss of H3K27me3 (silencing histone mark) or repressed by loss of H3K4me3 (activating
histone mark), upon signals for differentiation or development [65]. For instance, in AML CSCs, genes
involved in stem cell identity, proliferation and metabolic reprogramming were shown to be bivalently
marked with H3K4me3/H3K27me3, while in non-CSCs, H3K4me3 marks are lost to repress stem cell
identity genes [66]. Similarly, in glioblastoma, CSCs possess more open chromatin conformation due to
reduction of the silencing histone mark, H3K27me3, compared to non-CSCs, leading to a de-repression
of genes involved in tumor initiation [67].
In the case of PDAC, few studies have looked at the differences in the chromatin landscape
between CSCs and non-CSCs. Instead, the focus has more frequently been on deciphering the role of
particular chromatin writers, readers, or erasers in the pathogenesis of this disease. For example, EZH2,
a component of the Polycomb Repressive Complex 2 (PRC2), is a well-studied trimethylation writer of
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H3K27 whose increased expression in pancreatic cancer patients has been associated with not only a
greater incidence of positive nodes but also significantly larger tumors [68]. Chen et al. [69], for example,
used RNA interference to knockdown EZH2 and showed that EZH2 silencing decreased tumor growth
and the incidence of liver metastasis in a PDAC model. In terms of CSCs, van Vlerken et al. isolated
EpCAM+/CD44+/CD24+CSCs from the pancreatic cancer cell lines HPAC and Panc-1 and found
elevated levels of H3K27me3 compared with the non-CSC control population [70]. Similarly, EZH2
levels were also elevated in the CSC population. Interestingly, when they downregulated EZH2,
a decrease in CSC frequency followed by a significant gain in the non-CSC population was observed,
which the authors attributed to EZH2 loss driving the CSCs into a more differentiated state. It is
possible that apart from bearing more H3K27me3 histone marks, due to an increase in EZH2 protein
levels, the distribution of histone methylation in PDAC CSCs may differ from non-CSCs, which would
result in differential regulation of specific genes. That being said, it would be of interest to investigate
which are the most preferred regions occupied by H3K27me3 histone mark and if they show the
characteristic bivalent trait. In the aforementioned study, the authors also hypothesized that EZH2
expression could serve as a reporter assay to detect CSC activity. In line with this hypothesis, they
observed an increase or decrease in the percentage of EZH2high cells upon treatment with Gemcitabine
or Salinomycin, respectively, which mirrored changes in the percentage of EpCAM+CD44+CD24+
cells; however, more comprehensive experiments including transplantation assays in vivo would be
necessary to confirm whether EZH2 expression could be exploited as a marker to detect pancreatic
and other types of CSCs [70].
Apart from EZH2, which as previously mentioned is often overexpressed in cancer, another
histone methylation regulatory gene has been found to be frequently mutated in PDAC [71,72]. KDM6A
(also known as UTX) encodes for a histone H3K27me3 demethylase [73–75]. KDM6A is an integral
component of the complex of proteins associated with Set1 (COMPASS)-like complex, which apart
from the core proteins WDR5, RBBP5, DPY30, and ASH2L, also contains the methyltransferases
KMT2C or KMT2D, which mono-methylate H3K4 [76–79]. Data from The Cancer Cell Line
Encyclopedia [79] interrogating the copy-number and gene-expression changes in over 1000 human
cancer cell lines revealed selective copy-number losses and downregulation of KDM6A in PDAC.
Interestingly, loss of KDM6A expression or mutations were found more frequently in the more
aggressive squamous subtype of pancreatic cancer [72]. While ablation of KDM6A expression in
the pancreas of Pdx1Cre; Kdm6anull and Ptf1αCre; Kdm6anull mice did not change the global level of
H3K27me3, H3K27ac, H3K4me1 or EZH2, and these mice exhibited normal pancreatic histology,
when KDM6A loss was combined with mutant KrasG12D expression, mice developed aggressive,
metastatic squamous-like pancreatic tumors. Furthermore, KDM6A loss resulted in gene expression
changes independent of H3K27me3 that promoted squamous and quasi-mesenchymal differentiation
in female mice. Mechanistically, loss of KDM6A deregulated the COMPASS-like complex, disrupting
the super enhancer landscape to promote aberrant activation of oncogenes including TP63, MYC,
and RUNX3 [80]. Interestingly, demethylase-independent roles for KDM6A have been described
as important for stem cell homeostasis and developmental processes [81,82]. While this would
indicate an important role for KDM6A in regulating normal cell identity, in cancer this aspect has
not been extensively explored. In CSCs, a study performed by Taube et al., reported that fast-cycling,
differentiated subpopulations from multiple mammary cell lines showed significantly higher KDM6A
staining compared to their slow-cycling, stem cell-enriched counterparts [83]. Unfortunately, similar
studies in pancreatic CSCs are still lacking. Thus, considering the role of KDM6A in PDAC progression,
investigating the potential role of KDM6A in PDAC CSCs is warranted.
A crucial role for histone modifications in the progression of PDAC have been highlighted by
two recent studies [84,85]. While investigating the source of genetic heterogeneity across metastatic
sub-clones, Makohon-Moore et al., found that the genetic landscape of metastatic PDAC tumors
largely reflected that of the primary tumor [84]. In a follow-up study, Mc Donald, Li, and colleagues
interrogated the same group of samples focusing their attention on histone marks [85]. Surprisingly,
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they discovered major differences in the epigenetic landscape between primary tumor sub-clones that
seed regional sites (peritoneal) and those that seed distant sites (liver and lung). More specifically, in
peritoneal metastasis, histone 3 lysine 9 dimethylation (H3K9me2) was strongly enriched across large
block-like domains of heterochromatin (LOCKs), whereas the same regions displayed global reduction
in H3K9me2 in the distant metastasis and primary tumor precursors. Furthermore, the authors
observed differential gene expression and reduction in DNA methylation in the LOCKs from distant
metastases versus peritoneal metastases. They also looked at gene-rich euchromatin domains (ECDs),
defined by enrichment for acetylated H3K27 (H3K27ac) and H3K36 trimethylation (H3K36me3), and
found that distant metastases and primary tumor sub-clones displayed local reprograming of H3K27Ac
and H3K36me3 specifically over differently expressed genes within ECDs. Thus, this study discovered
that substantial epigenetic reprograming occurs at sites of heterochromatin and euchromatin and that
this differs between regional and distant metastasis. Later, in the same year, Roe and colleagues also
studied chromatin regulation in PDAC metastasis, but with a focus on enhancer regions [86]. In paired
PDAC organoids derived from primary KPC mouse (KRas+/LSLG12D; TP53R172H/+; Pdx1-Cre) tumors
and metastases, genome-wide profiling revealed regions with increased levels of the active enhancer
mark H3K27ac (GAIN regions) and regions with decreased H3K27ac (LOSS regions), although global
H3K27ac levels were similar across the samples. The large majority of GAIN and LOSS regions occurred
in enhancers, and GAIN enhancers exhibited enrichment of H3K4me1 in metastatic organoids without
changes in chromatin accessibility. Furthermore, the FOXA1 pioneer factor was enriched in GAIN
regions and cooperated with GATA5 to remodel enhancer histone marks to promote PDAC progression
and metastasis in vivo.
Taken together, both studies have contributed substantially to furthering our understanding
of the molecular and epigenetic mechanisms that drive PDAC metastasis, but both studies lacked
any interrogation of the role of CSCs in this process. Multiple studies have shown that circulating
tumors cells (CTCs) can intravasate into the bloodstream promoting the generation of micro-metastatic
reservoirs, some of which can progress to macro-metastatic disease [87,88]. In theory, a small fraction
of these CTCs should have CSC activity and/or properties. While additional studies would still
need to be performed to better understand the relationship between CSCs and CTC populations in
PDAC, the aforementioned studies may offer an attractive idea for looking at chromatin patterns in
different cell populations from primary and metastatic tumor sites to reveal if epigenetic reprograming
is occurring ubiquitously or if it is a unique feature of a particular population or pool of cells.
3. Role of Non-Coding RNAs in CSCs
Data from the Human Genome Project indicate that only around 20,000 genes of the human
genome encode for proteins [89]. Thus, the vast majority of transcribed RNAs are not translated
into proteins and are known as non-coding RNAs (ncRNAs) [90–92]. ncRNAs used to be considered
“junk RNAs”; however, an increasing body of evidence now suggests that ncRNAs are critical for
epigenetic, transcriptional, posttranscriptional, and translational regulation of gene expression in both
physiological and pathological conditions [93–95]. Similarly, it has been shown that ncRNAs, such as
microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), can regulate cancer cell stemness and
are necessary for the maintenance of the CSC pool. Therefore, a more comprehensive understanding
of the role of ncRNAs in CSC regulation could reveal novel strategies to eradicate this population of
cells, responsible for tumor relapse and metastasis.
Based on their size, ncRNAs can be divided in two major groups: small ncRNAs refer to ncRNAs
shorter than 200 nucleotides, while long ncRNAs (lncRNAs) refer to ncRNAs composed of 200 or
more nucleotides. Small ncRNAs can be further categorized into subcategories based on their length,
function, and subcellular localization such as microRNAs (miRNAs), short interfering RNAs (siRNAs),
piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), short hairpin RNAs (shRNA), and
other short RNAs [96]. These small ncRNAs have been implicated in various aspects of CSCs biology.
Of the small ncRNAs, in this review we will primarily discuss the role of miRNAs in CSCs biology.
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3.1. Role of miRNAs in CSCs
miRNAs are small (20–25 nucleotides) ncRNAs and key players in the post-transcriptional
regulation of genes. More than 80% of mammalian genes are under their direct or indirect control,
highlighting that almost every cellular function is tightly regulated by miRNAs. Indeed, miRNAs
show very specific patterns of expression across different tissues and cell types, and approximately
2000 miRNAs have already been identified in the human genome. Their mechanism of action is based
on the recognition of small (6–8 nt) sequences present in their target mRNAs [97]. Due to the small size
of these recognition sites, one miRNA can potentially recognize and regulate several mRNA targets,
and a single mRNA can be regulated by more than one miRNA [98]. This dynamic regulation has
revealed miRNAs as critical regulators of a multitude of cellular processes, and thus, their deregulation
can have significant pathological consequences, contributing to disease onset and development.
Mature miRNAs are loaded into the interference multiprotein complex (RISC), where translational
repression takes place. Inside RISC, miRNAs recognize their target mRNAs by base-pair complementarity
of the miRNA seed sequence with the 3′ untranslated region (UTR) of the mRNA. When complementarity
between the seed sequence and mRNA target sequence mRNA is perfect, cleaving inside the RISC
complex occurs. When complementarity is only partial, mRNA translational repression or degradation
occurs, involving the recruitment of deadenylase complexes tasked with the removal or shortening of the
mRNA poly-A tail [99]. miRNA binding sites have also been identified in the 5′ UTR and open reading
frame regions.
It has been widely demonstrated that miRNAs can also be secreted to the extracellular
environment/milieu, where they can travel to distant sites and exert their regulatory effects on new
target cells. miRNAs have been detected in a wide range of cell-free body fluids such as urine, serum,
or saliva. Their secretion is believed to not only be a highly regulated process, but the selection of
which miRNAs will be secreted is also believed to be tightly controlled and not a random process [100].
Thus, secreted miRNAs may be as functionally relevant as their non-secreted counterparts. As stated
above, the deregulation of miRNAs (over-expression or silencing) has been associated with several
different pathologies, thus physiological or pathological regulation of intracellular miRNAs may give
rise to different profiles of secreted miRNAs. Indeed, changes in miRNA serum profiles have been
used as biomarkers for a wide-range of diseases including cancer [101], cardiovascular diseases [102]
or neurodegeneration [103], among others.
In the last 10 years, miRNAs have also provided new insights into gene regulation implicated
in tumorigenesis and CSC biology [104]. Several miRNAs involved in CSC biology in different solid
tumors have been identified: (i) miR-5703, miR-630, miR-1246, miR-424-5p and miR-320b were all
deregulated in ovarian CSCs [105]; (ii) miR-34a, miR-200b/c, miR-203 and miR-137 appear to be critical
in CRC CSCs [106]; (iii) the miR-200 family and miR-let7 family are crucial for CSC dynamics in breast
cancer [107]; (iv) miR181-5p, miR153 and the miR17-92 cluster are relevant for the pancreatic CSC
sub-population [45,108,109]. Remarkably, secreted exosomes from CSCs also orchestrate autocrine and
paracrine functions, which alter the tumor microenvironment, as well as the growth and progression of
the tumor. CSC-derived exosomes contain stemness-specific proteins, miRNAs capable of promoting
self-renewal, and survival factors, all of which can contribute to tumor heterogeneity and tumor
progression [110].
As previously mentioned, pancreatic CSCs undergo EMT, contributing to relapse and
chemoresistance, and miRNAs are one of the major epigenetic mechanisms involved in the EMT
process. The first association between a miRNA and EMT was described for the miR-200 family,
which consists of miR-200a/b/c, miR-141 and miR-429. In 2008, Gregory et al. showed that decreased
expression of the miR-200 family led to enhanced ZEB1 and ZEB2 expression [111]. Via a reciprocal
feedback loop, ZEB1 and miR-200 family members repress the expression of each other. Later,
Brabletz et al. would show that miR-200 members also target Jagged1 and the mastermind-like
coactivators MAML2 and MAML3, important components of the Notch pathway. Specifically,
the authors showed that in PDAC, ZEB1-mediated reduced miR-200 expression promoted Notch
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activation and indirectly induced stemness maintenance [112]. Additional miRNAs regulating EMT
transcription factors have also been described and include miR-29b, miR-30a and miR-205 [113–115].
Moreover, relevant EMT molecules are directly regulated by miRNAs, including: E-cadherin
(miR-9), N-cadherin (miR-194), Nestin and Star1 (miR-661), pulmonary adenoma resistance 3 protein
(miR-491-5p), which is engaged in tight junction alteration and p120 (catenin δ1) (miR-197) [116–120].
Thus, miRNAs are necessary for cells to enter EMT, and consequently they may also act as regulators
of de novo CSC-genesis as it has been shown that EMT activation can give rise to CSCs [121].
Several miRNAs have been directly linked to pancreatic CSC biology. For example, we reported
that the miR17-92 cluster plays an anti-CSC role in PDAC, thus pancreatic CSCs downregulate the
expression of this cluster, via DNMT1-mediated methylation, to maintain their stem state by preventing
degradation of key CSC mRNAs [109]. Nalls et al., demonstrated that the miR-34a regulates CSC
characteristics and therefore pancreas cancer progression [122]. miR-34 regulates Notch pathway
proteins and BCL-2, and it can counteract the tumor suppressing function of p53 in p53-deficient
human PDAC tumors [123]. miRNAs associated to RAS proteins, altered in the majority of PDAC
tumors, have also been identified. For example, miR-217 specifically targets the KRAS oncogene [124].
miR-96 is also a potent negative regulator of KRAS signaling, directly targeting KRAS and having
anti-proliferative, pro-apoptotic and anti-metastatic effects [125]. Downregulation of miR-126 and
let-7d contributes to PDAC transformation by post-transcriptional upregulation of KRAS [126]. miR-21
has also recently been linked to RAS, through activation of AP-1 in response to RAS [127], and
activated/mutated KRAS (G12D) stimulates the promoter of miR-21 in human PDAC cells.
While the cell of origin in PDAC is unknown, it is believed that PDAC arises from a stepwise
process from low-grade to high-grade pancreatic intraepithelial neoplasias (PanINs) with accumulation
of specific genetic mutational events (e.g., mutations in KRAS, p16, p53, etc.). Initial PDAC lesions
exhibit different miRNA expression profiles depending on severity. For example, miR-155 has been
shown to be significantly overexpressed in PanIN-2/PanIN-3 lesions, and the levels of miR-155
increased from PanIN-2 to PanIN-3 lesions, strongly suggesting that miR-155 activation could be an
initial event in tumor progression, perhaps at the level of the cell of origin [128]. Moreover, Yu et al.,
identified several miRNAs including miR-378, miR-130b, miR-133a, miR-151-5p, miR-148a/b, miR-185,
miR-331-3p/5p, miR-200c, miR-330-3p, miR-34c-5p, miR-129-3p, and miR-423-5p to be overexpressed
in low-grade PanINs (PanIN-1 or PanIN-2), while others have shown that different miRNAs, such
as miR-196b, are exclusively expressed in advanced PanIN-3 lesions and undetectable in low-grade
PanIN lesions [129]. Thus, it is interesting to hypothesize that miRNA expression in PDAC precursors
could cooperatively function with genetic mutations to give rise to the CSC population.
Apart from their tumorigenic and self-renewal capacity, CSCs also significantly contribute to
the radio and chemoresistance inherent of PDAC. Gemcitabine is the standard of care for PDAC,
and several miRNAs have been described to be related to Gemcitabine response. miR-145, acting
as sponge for the long intergenic ncRNAs (lincRNAs) linc-DYNC2H1-4, regulates EMT and CSC
properties, impacting resistance to Gemcitabine in PDAC cells [130]. miR-205, a miRNA associated to
CSC phenotypes in PDAC, is highly downregulated in Gemcitabine-resistant cells, and a reduction
in CSCs, EMT and chemoresistance markers is observed when miR-205 is overexpressed, strongly
suggesting that miR-205 re-sensitizes Gemcitabine-resistant PDAC cells to Gemcitabine [131]. miR-200c
confers therapy resistance in several solid tumors, including PDAC. Chemoresistance, targeted therapy
resistance and radiotherapy resistance is observed when miR-200c is deregulated as it impacts EMT
processes, affecting important signaling cascades such as TGF-β, PI3K/Akt, NOTCH, VEGF, and NF-κB
signaling [132]. The miR-17-92 cluster, mentioned above, is also downregulated in chemoresistant
CSCs. In fact, overexpression of miR-17-92 reduced chemoresistance to Gemcitabine, CSC self-renewal
and tumorigenicity in animal models, through inhibition of NODAL/ACTIVIN/TGF-β1 signaling and
targeting of p21, p57 and TBX3 [109]. miR-1246 is also related with tumor-initiation and drug resistance
induction targeting CCNG2 expression. Indeed, higher levels of miR-1246 have been correlated with
a worse prognosis in Gemcitabine-treated patients, correlating with lower CCNG2 expression in
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primary PDAC tumors [133]. Therefore, modulation of miRNAs in PDAC and in PDAC CSCs has
emerged as an attractive approach for restoring chemosensitivity to Gemcitabine and potentially other
chemotherapies [134].
As previously mentioned, miRNAs can be secreted to the extracellular space and body fluids,
including blood; therefore, the easy detection of miRNAs in serum or plasma represents a very
useful non-invasive methods for early diagnosis and monitoring of treatment response. Until now,
the carbohydrate antigen 19-9 is the only US Food and Drug Administration (FDA) approved marker
for the diagnosis of PDAC and evaluation of treatment response; however, it is widely known that
its utility as a biomarker is limited due to its restricted sensitivity and specificity. Therefore, there is
an unmet and urgent clinical need for novel and more precise biomarkers in PDAC. miRNA levels
in the blood could provide very valuable information in the early diagnosis of PDAC, stratification
and treatment response, as observed in other solid tumors, allowing for more efficient management of
PDAC patients in the context of personalized medicine.
3.2. Role of lncRNA in CSCs
lncRNAs are a class of ncRNAs that are longer than 200 nucleotides, do not encode for proteins
and are found to have limited expression across different tissues. As reported in the literature,
dysregulation of lncRNAs has been found in various types of cancers, such as leukemia, breast
cancer, gastric cancer, CRC, HCC, and lung cancer [135–139]. Most lncRNAs are transcribed by RNA
polymerase II, and around ~13,000 lncRNAs have been confirmed to exist and more than half of them
have been found between genes, known as lincRNAs [140,141]. Others lncRNAs include overlapping,
antisense, and intronic lncRNAs [89].
LncRNAs can regulate the expression of genes via four mechanisms of action [142,143]. They can
function as (1) Signals: functioning as a molecular signal or indicator of transcriptional activity, thus
reflecting the biological outcome of gene expression; (2) Decoys: lncRNA can bind and titrate away
proteins or RNA targets; (3) Guides: lncRNA can bind RNA-binding proteins and guide them to either
a near or distant target gene locus and/or (4) Scaffolds: helping to assemble different proteins to form
RNA:protein complexes important for the initiation of specific biological functions.
Multiple studies have revealed that lncRNAs regulate pluripotency via several mechanisms
including histone modifications, working as scaffolds or by forming competing endogenous RNAs
(ce-RNA) for miRNAs that repress expression of pluripotency-associated gene. Moreover, lncRNAs
can influence CSC-genesis and plasticity by altering signaling pathways related to self-renewal or
pluripotency or by modulating chemoresistance and EMT processes [144,145].
In the case of PDAC, the field has recently started to explore how lncRNA molecules could
contribute to the development and progression of this cancer, and more specifically, how lncRNAs
can influence pancreatic CSC biology. Among the first lncRNAs explored in PDAC CSCs was
metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). Feng et al., found higher
expression of MALAT1 in CD133-positive PDAC CSCs when compared to their CD133-negative
counterparts [146]. Moreover, when they knocked-down MALAT1 in PDAC cells, these cells showed
a reduction in both in vitro and in vivo stemness properties. Specifically, the authors observed a
decrease in the expression of pluripotency genes SOX2, BMI1 and NANOG, less ability to form spheres
and colonies, and MALAT1 knock-down cells showed decreased in vivo xenograft growth capacity.
This study, however, did not deeply explore the exact mechanism(s) by which MALAT1 regulated
pancreatic CSCs. Since then, several studies have investigated the molecular role of MALAT1 in other
tumor entities and in CSCs. As with most factors, MALAT1 expression varies across different tumor
types. For example, its over-expression was observed in liver, cervical, colon and gallbladder cancer,
and its expression has been shown to be a predictive marker in stage I non-small cell lung cancer
patients and in stage II/III CRC patients [147–151]. In contrast, MALAT1 levels have been shown to be
low in glioma tissue. At the molecular levels, Han et al. showed that low levels of MALAT1 promoted
cancer cell proliferation and metastasis by activating the ERK/MAPK signaling pathway in the glioma
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stem cell line SHG139S [152]. In liver cancer stem cells, Wu et al. showed that MALAT1 overexpression
resulted in more RNA polII, P300, CREPT loading onto the promoter region of telomere repeat-binding
factor 2 (TRF2), enhancing TRF2 expression at the level of transcription and its phosphorylation and
SUMOylation. TRF2 is involved in telomere maintenance and protection, thus in this study MALAT1
promoted liver CSCs through telomere regulation [150]. Whether MALAT1 regulates ERK/MAPK
signaling or telomere stability in pancreatic CSCs is still unknown.
HOTTIP (HOXA transcript at the distal tip) is another lncRNA, shown to regulate stemness
and tumorigenicity in pancreatic cancer. It is a lncRNA located near chromosome (chr) 7p15.2 and
transcribed from the 5′ tip of the HOXA locus. Alteration of HOTTIP in PDAC CSCs affected sphere
formation, expression of the pluripotency genes NANOG, OCT4 and SOX2, expression of known
CSC markers ALDH1, CD44 and CD133 and tumor growth. In their study, Fu et al. proposed a
very interesting mechanism for how HOTTIP could exert its role on CSCs, which included its direct
binding to the adapter WD Repeat Domain 5 (WDR5) protein [153]. This protein can contribute to
histone modification, as part of the mixed-lineage leukemia 1 (MLL1)/MLL complex that is involved
in methylation and dimethylation at Lys-4 of histone H3, a specific tag for epigenetic transcriptional
activation. HOTTIP could target WDR5/MLL complexes across the HOXA9 locus, driving histone
H3 lysine 4 trimethylation and HOXA9 gene transcription. Moreover, HOXA9 regulation by HOTTIP
could further mediate the activation of the Wnt pathway in pancreatic CSCs by promoting the
expression of Wnt genes. Thus, the HOTTIP/HOXA9 axis may regulate PDAC CSCs by modulating
the Wnt/β-catenin signaling pathway.
An increasing number of lncRNAs have also been implicated in the regulation of EMT acting as
either promoters (pro-EMT) or antagonizers (anti-EMT), often by functioning as competing endogenous
RNAs (ceRNAs) for miRNAs involved in EMT regulation or by mediating epigenetic silencing via
the recruitment of PRC2. The lncRNA-activated by TGF-β (lncRNA-ATB) is an excellent example
of how a lncRNA can modulate different CSC pathways to trigger an EMT program to enhance cell
migration and invasiveness. In the study by Yuan and collaborators, the authors found the expression of
lncRNA-ATB to be induced following TGF-β treatment in HCC cells [154]. Overexpression of wild-type
lncRNA-ATB was able to induced EMT and tumor cell invasion and facilitated disseminated tumor
cell colonization, thus mimicking the pro-metastatic role of TGF-β. Mechanistically, this lncRNA-ATB
was shown to sequester miR-200, a known repressor of EMT and tumor invasion, which can target the
3′UTRs of ZEB1 and ZEB2 [111,155]. In this context, lncRNA-ATB functions as a ceRNA, freeing ZEB1
and ZEB2 mRNAs from miR-200 post-translational inhibition. The resulting increase in ZEB1 and ZEB2
levels trigger the EMT program, ultimately leading to an enhanced invasive potential of HCC cells
in vitro and in vivo. The role of lncRNA-ATB in cancer metastasis; however, goes beyond its role in
tumor invasion because the same study showed it to be an equally important player in the colonization
of the metastatic site. This effect was not dependent on sponging miR-200, but rather it involved
additional pathways crucial for the maintenance of the CSC state, including JAK/STAT signaling.
By physically interacting with the IL-11 mRNA, lncRNA-ATB could increase its stability, translation,
and secretion, all of which activated STAT3 signaling in an autocrine manner. The activation of
this autocrine loop is required for enhancing the effect of lncRNA-ATB on HCC cell colonization.
Interestingly, in a study by Shibin et al., the authors found lncRNA-ATB expression levels to be
significantly downregulated in PDAC tissues versus paired adjacent normal tissues [156]. Additionally,
the decrease in expression levels positively correlated with lymphatic metastasis and clinical stage,
suggesting that in PDAC, this lncRNA can function in a manner opposite of that described for HCC,
suppressing invasion and metastasis. Further studies, however, are still needed to explore the exact
mechanism by which lncRNA-ATB functions in PDAC.
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An example of lncRNAs found to be both overexpressed in PDAC and involved in EMT are lncRNA
plasmacytoma variant translocation 1 gene (lncRNA-PVT1) and lncRNA- taurine up-regulated 1
(lncRNA-TUG1) [157,158]. Both lncRNAs play important roles in regulating PDAC cell proliferation
and migration. lncRNA-PVT1 works partially by regulating p21 expression, and in the case of
lncRNA-TUG1, this lncRNA is similar to lncRNA-ATB, in that it acts as a ceRNA, sponging miR-382.
When TUG1 was overexpressed in PDAC cells, miR-382 was significantly downregulated; however,
TUG1 knockdown significantly increased the level of miR-382, impairing PDAC cell migration and the
expression of EMT markers. This sponging effect allowed expression of miR-382 target genes, including
EZH2, which can promote EMT, invasiveness and metastasis via silencing of the E-cadherin promoter
by H3K27 trimethylation [159,160]. As mentioned above, EZH2 is highly expressed in PDAC CSCs and
its levels could serve as a readout of CSC activity, thus it would be interesting to see if lncRNA-TUG1
could also serve as a surrogate marker for PDAC CSC activity.
Finally, Arnes et al. [161], recently generated a catalogue of PDAC-associated lncRNAs and
showed that lncRNAs can be used to associate patients into two predominant mutant KRAS allele
clusters. Interestingly, these clusters correlated with the two prominent subtypes categorized to
date for PDAC tumors, the epithelial (Cluster 1) and squamous (Cluster 2) subtypes. In addition,
a clear reduction in disease-free survival was observed for those patients from Cluster 2 relative to
the other clusters. Of the lncRNAs identified, the authors functionally evaluated FAM83H-AS1 and
LINC0067, as both were found in recurrent amplified genomic regions. Interestingly, LINC00673 was
shown to be a major regulator of the epithelial state of PDAC cells, as its loss promoted acquisition of
mesenchymal markers such as vimentin, loss of epithelial markers and enhanced tumor cell migration
both in vitro and in vivo, demonstrating that modulation alone of LINC00673 can affect PDAC cell
plasticity, which is a key feature of CSCs. Interestingly, it was recently shown by Zheng et al., that a
G>A change in exon 4 of LINC00673 (at rs1111655237) in a percentage of PDAC patients creates a new
miR-1231 binding site [162]. This results in LINC00673 sequestration, preventing it from promoting
PTPN11/SHP2 phosphatase degradation via ubiquitination. The subsequent stabilization and increase
in SHP2 levels is believed to confer susceptibility to tumorigenesis. Indeed, SHP2 is overexpressed
in PDAC, and Algül and collaborators recently showed that mutant KRAS is dependent on SHP2
during carcinogenesis, and this interaction can be abrogated with dual SHP2/MEK inhibition [163].
Together, these data show that lncRNAs in PDAC are biologically relevant, their interacting partners
can play important roles in tumorigenesis, and targeting lncRNAs or their protein partners can be
therapeutically beneficial and could potentially affect PDAC cell plasticity.
While more research is required to fully understand the role of lncRNAs in tumor biology, CSC
biology and in PDAC, we performed an analysis of the expression of several published lincRNAs in
CSCs versus non-CSCs derived from several low-passage PDAC patient-derived xenografts. Our initial
analyses of the expression of HOTAIR, IRX5, MKLN2, SFPQ, LPHN2 and ZNF673 demonstrate that
CSCs generally over-express these lncRNAs compared to their non-CSCs counterparts, although
differences were observed across PDAC tumors, indicating patient-to-patient variability and perhaps
sub-type-specific differences (Figure 2). While preliminary, these unpublished results demonstrate that
lincRNAs are differentially expressed in pancreatic CSCs and their role in CSC stemness may be more
important than previously recognized.
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4. Epigenetic Therapy in Cancer
Unlike genetic mutations, which are considered irreversible, epigenetic changes are reversible.
Thus, drugs that alter epigenetic modifications or marks could, in theory, restore the epigenetic balance
in cancer (Figure 3). Epigenetic therapy therefore aims to reverse the genetic modifications/alterations
present in cancer to restore the “normal epigenome landscape”. Among the first epigenetic drugs
tested to treat cancer were DNA methylation inhibitors [22]. Azacitidine (5-azacitidine) and Decitabine
(5-aza-2′-deoxycytidine), are the two most widely studied DNMT inhibitors that act as analogues of
cytosine. During DNA replication, both inhibitors are incorporated into the DNA forming covalent
bonds with the DNA methyltransferase DNMT1, preventing its methyltransferase capacity [164,165]
and leading to its subsequent degradation [166]. Initially these drugs showed promising results
in hematological malignancies, leading to their approval by the US FDA for the treatment of
myelodysplastic syndromes; however, their use in solid tumors remains limited due to their high
cytotoxicity [167–169]. Interestingly, recent studies in leukemia and epithelial tumor cells have
demonstrated that low doses of DNMT inhibitors are more effective in maintaining decreased DNA
methylation and associated re-expression of silenced genes [170]. Moreover, low doses of DNMT
inhibitors also reduced overall tumorigenicity and the percentage of CSCs within the tumor. Nalls et al.
showed that pancreatic CSCs are sensitive to Decitabine. Treatment with Decitabine strongly inhibited
cell proliferation, self-renewal, invasion, and induced apoptosis of CSCs through re-expression of the
tumor suppressor miRNA-34 [122]. In addition to Decitabine-mediated induced apoptosis, Decitabine
can also induce differentiation of PDAC progenitor cell lines, including MIA PaCa-2 [171] and
Panc-1 [172]. Indeed, drug-triggered differentiation is an attractive approach in epigenetic therapy and
has long been considered a strategy for targeting CSCs. For example, in prostate cancer, CSCs treated
with the Decitabine showed decreased expression of the pluripotency-associated genes OCT4 and
NANOG and increased expression of the differentiation markers CK5, CK8, Nkx3.1, and PSA/PSP94.
Re-activation of androgen receptor, found to be methylated in prostate CSCs, was determined to
be the mechanism behind differentiation induction mediated by Decitabine. Decitabine-induced
differentiation led to a significant decrease in the self-renewal and tumorigenic capacity of the treated
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prostate CSCs. In addition, low doses of a newer DNMT1 inhibitor, SGI-110, was recently shown to
reprogram ovarian CSCs to a more differentiated non-CSC state [173]. Lastly, we have also shown that
the less toxic DNMT1 inhibitor Zebularine can potently abrogate the in vivo and in vitro pluripotency
and tumorigenicity of PDAC CSCs by promoting differentiation of CSCs toward less tumorigenic
non-CSCs [45]. Since current available chemotherapeutics can effectively target fast proliferating bulk
tumor cells, leaving slow-cycling CSCs unaffected, therapies based on DNMT inhibitors that push
CSCs to a more differentiated state could offer promising alternatives to force CSCs into a state where
they are more permissive and sensitive to standard therapies.
HDAC inhibitors (HDACIs) are another group of epigenetic drugs that can act on both CSCs
and bulk non-CSCs. HDACIs can induce CSC differentiation, inhibit their self-renewal capacity,
reverse their chemo/radiotherapy resistance, or promote their death. For example, it was recently
shown in triple-negative breast cancer that the selective inhibitor of class I HDACs, Entinostat,
can decrease the CSC population and abrogate their EMT phenotype [174]. In pancreatic cancer,
Trichostatin A (TSA) can strongly inhibit the growth of pancreatic cancer cell lines via cell-cycle
arrest at the G2 phase and induced-apoptotic cell death [175]. Chien et al. showed that Belinostat,
another HDACI, can suppress human PDAC cells via multiple pathways [176]. Specifically, Belinostat
treatment decreased PDAC cell growth and increased apoptosis, which was associated with blocking
the AKT/mTOR pathway. Interestingly, Belinostat also blocked hypoxic growth-related signals. Alone
or in combination with Gemcitabine, a significant decrease in the size of human pancreatic tumor
growth was observed in immunodeficient mice. Furthermore, treatment of the pancreatic cancer
cell line Panc-1 with Mocetinostat reduced ZEB1 expression, causing up regulation of the stemness
inhibiting miRNA-203 molecule, resulting in reduced expression of CSC-associated markers, such as
CD133, as well as the sphere-forming capacity and sensitization of undifferentiated ZEB1-expressing
cells to Gemcitabine [177]. Thus, all these studies together suggest that targeting histone deacetylases
could be a very promising strategy for treating PDAC, and while HDACIs clearly affect PDAC cells in
preclinical settings, HDACIs have yet to show relevant antitumor activity in clinical studies in PDAC
patients. This certainly reflects the very poor state of PDAC patients at the time of diagnosis, when
tumors in most patients have already locally advanced and spread to distant organs, making treatment
with HDACIs relatively ineffective. It remains to be determined if HDACIs would be more effective if
initiated at early times. In addition, the complexity of the actions of HDACs in PDAC and in PDAC
CSCs may be particularly unique, limiting even further the efficacy of HDACIs. Interestingly, a 2012
study by Woodward WA and colleagues showed that the HDACIs Suberoylanilide Hydroxamic Acid
(SAHA) or Valproic acid, could induce the dedifferentiation of ALDH1-negative non-CSCs resulting
in the de novo production of quiescent ALDH1-positive CSCs [178]. While potentially alarming,
the same group would later show that dedifferentiation of cancer cells to CSCs was concomitant
with metabolic reprograming, such as upregulation of G6PD, a rate-limiting enzyme in the pentose
phosphate pathway. The authors exploited this metabolic reprogramming induced by HDACIs
by using two G6PD inhibitors, 6-aminonicotinamide and dehydroepiandrosterone, to successfully
target Valproic acid-induced ALDH-positive cells, decreasing sphere formation efficiency and ALDH
activity [179]. Thus, these studies highlight that HDACIs could have cell population specific effects
and could potentially reprogram non-CSCs into CSCs. Therefore, more comprehensive analyses of the
effect(s) of HDACIs on CSCs and on different sub-populations of CSCs is necessary before HDACIs
are considered as possible treatment options for cancer patients, including pancreatic cancer patients.
A better understanding of the exact mechanism(s) of their action and their related effects on non-CSCs
will help predict treatment outcome and potential harmful side effects.
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Figure 3. Targeting the epigenome of Cancer Stem Cells. The variability of the epigenetic mechanisms
within cells offers a wide array of targeting strategies. Differentiation therapy is one attractive
approach that, in combination with chemotherapeutics, can potentially eliminate both fast proliferating
cancer cells and CSCs, once pushed into a more differentiated state. DNMTs can be targeted with
several drugs, such as Aza-dC (Decitabine), SGI-110 or Zebularine, decreasing DNMT1 protein levels,
decreasing global methylation and impairing CSCs biology. HDAC inhibitors (HDACI), such as
Entinostat, Belinostat and Mocetinostat, have also shown promising results but these drugs could
have population specific side-effects. Both miRNAs and lncRNAs also represent interesting target
molecules. miRNAs can be complexed with drug-loaded micelles and delivered successfully to cancer
cells. lncRNAs can be targeted with GapmeRs or small molecule inhibitors that disrupt lncRNA-protein
interactions. Importantly the field is progressing to improve delivery methods and in vivo applicability
for these molecules.
As a class of molecules, miRNAs hold particular therapeutic potential because they can regulate
various gene targets belonging to a specific pathway, or they can modulate several target genes
across several independent pathways [180,181]. Over the past years, the delivery method for
miRNAs has been substantially improved allowing for the efficient introduction of miRNAs into
pancreatic cancer cells and subsequent suppression of these cells in animal models. For example,
liposomal nanoparticles carrying miR-34a were able to significantly inhibit the growth of orthotopic
xenografts models where reduction of CSC markers was also observed [182]. miR-145-loaded magnetic
nanoparticle formulations (miR-145-MNPF) have also been successfully delivered to PDAC cells,
demonstrating a functional inhibitory effect on growth, invasion and motility via inhibition of
MUC13-associated oncogenic protein, HER2, pAKTSer473, and restoring p53 levels [183]. Furthermore,
co-administration of antisense oligonucleotides (ASOs) of miR-21 and miR-221 reduced primary tumor
growth and metastasis of pancreatic cancer [184]. Other studies have revealed that co-administration of
miRNA therapeutics and anti-cancer drugs can improve response and/or overcome chemoresistance.
The co-delivery of ASO-miR-21 and Gemcitabine induced more cell apoptosis, and the administration
of miR-205 and Gemcitabine enhanced chemosensitivity of Gemcitabine-resistant pancreatic cell
lines [185,186]. In addition, micelles encapsulating the Hedgehog inhibitor GDC-044 and complexed
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with let-7b effectively inhibited pancreatic tumor growth in vivo, by decreasing tumor cell proliferation
and promoting apoptosis [187].
Similar to miRNAs, lncRNAs are another attractive therapeutic target considering their tightly
controlled transcriptional regulation, tissue-specific expression and frequent dysregulation in disease.
One of the first evidences that lncRNAs could have therapeutic value came from studies performed
in bladder cancer. Intratumoral injection of plasmids encoding for the A subunit of diphtheria
toxin, under the control of lncRNA H19 regulatory sequences, led to tumor reduction in bladder
cancer xenograft mouse models [188]. Following this work, several phase I/II clinical trials were
initiated in different cancer types, including one in PDAC, showing that local administration of
BC-819, in combination with systemic chemotherapy, may prove therapeutically beneficial for the
treatment of this disease [189]. Although lncRNAs represent appealing pharmacological targets, their
inhibition in vivo remains a challenge. Many limitations still need to be overcome, such as their
extensive secondary structure hindering the design of effective small molecule inhibitors, in vivo
toxicity and efficient intratumor delivery. Nonetheless, one amenable approach could be the use of
small molecules that disrupt the interactions between lncRNAs and proteins to alter their steady
state levels in target cells. It is well accepted that lncRNAs can bind EZH2 [190] or β-catenin [191],
and small molecules could be developed to block these interactions and prevent lncRNA/protein
binding. Similar approaches have been used to disrupt the miRNA processing machinery [192,193].
Taken together, these delivery efforts, along with further elucidation of lncRNA regulatory mechanisms,
will ultimately lead to the development of effective therapeutic strategies that target lncRNAs in vivo.
5. Concluding Remarks
In the past, it has been common to define CSCs as cells with the “fixed” ability to constantly
“maintain” their so-called “CSC-phenotype”; however, several recent studies have challenged this view
by demonstrating a very dynamic conversion between cancer cell populations (non-CSCs) through
trans-differentiation and reprograming events. These trans-conversion events likely occur when CSCs
are directly targeted and the tumor (including the tumor microenvironment) senses the loss of the CSC
pool. For example, in glioblastoma it has been shown that therapeutic doses of Temozolomide (TMZ)
can increase the glioblastoma stem cell (GSC) pool, and the increase was not due to an enrichment
in GSCs due to the elimination of non-GSCs, but rather due to the capacity of non-GSC cells to
“phenotypically shift” to a GSC-like state, resulting in de novo GSC-like cells that expressed stem and
pluripotency markers, including CD133, NESTIN, SOX2 and OCT4 [194]. Moreover, these new GSCs
served as a reservoir for initiating tumor relapse. A similar effect was observed in breast cancer cells
following treatment with the HDACIs SAHA and Valproic acid, as mentioned above. Moreover, two
recent studies targeting LGR5+ colon cancer cells in vivo have shown that non-CSCs can be a pulled
out of the tumor bulk population to replenish the CSC compartment when CSCs are eliminated [20,21].
Both studies highlight that tumors can be maintained by proliferative non-CSCs that respond to the
loss of the CSC pool, leading to rapid tumor re-growth when treatments targeting the CSCs are stopped.
Thus, stemness is likely not a hardwired or fixed trait as previously believed but rather a dynamic
property fueled by the heterogeneity of the tumor and the inherent and perhaps unappreciated cellular
plasticity of non-CSCs. From a therapeutic perspective, this implies that merely targeting the CSC will
not be curative as non-CSCs can quickly replenish the CSC pool. The dynamic nature of stemness
implies that this process must be fast enough to allow for rapid acquisition of specific CSC traits,
such as aggressiveness, ability to metastasize, drug resistance, etc.—all of which are important for
tumor growth and relapse. Many stem cell-related genes are found in a bivalent state, with activating
and repressing histone marks which can allow for rapid activation or inhibition. Consequently,
it is very probable that epigenetic changes and modifications are the determining factor in this fast
and rapid plastic process. Thus, in the new age of the CSC concept and with our ever-growing
understanding of cellular plasticity, it is even more important that we dissect the mechanism by
which epigenetic modifications play a role in trans-conversion/plasticity to make future anti-CSC
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strategies more effective. We envision the future of cancer therapies consisting of inhibitors that target
highly proliferating cells, active CSCs, quiescent CSC and the epigenetic mechanisms regulating cancer
cell plasticity.
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